Pathology: mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 positive;
mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | ||
MYSTIC (DT ; all population), 2020 | MYSTIC (DT ; PDL1>25%), 2020 | ||
durvalumab plus tremelimumab | 2 | T1 | T1 |
Standard of Care (SoC) | 0 | T0 | T0 |